FocusIMMUNOTHERAPY

PD-1 and CTLA-4: Two checkpoints, one pathway?

See allHide authors and affiliations

Science Immunology  12 May 2017:
Vol. 2, Issue 11, eaan3864
DOI: 10.1126/sciimmunol.aan3864

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

PD-1–centered therapies rely on CD28 activation to promote anti-tumor immunity.

View Full Text